Truscreen Group Ltd. · NZX:TRU
Truscreen — Investor Presentation (February 2024)
33 slides from Truscreen's investor presentation, Feb 28, 2024
Slide 1: TruScreen FY2024: Accelerating growth
For personal use only TruScreen Group Ltd NZX|ASX: TRU FY2024 Accelerating growth February 2024 Beata Edling CEO TruScreen
Slide 2: This Presentation
2 This Presentation For personal use only Screening for Cervical Cancer, world’s priority in 2024 About TruScreen technology Key achievements YTD financial year 2024 China, our biggest market and growth potential Accelerating sales growth in financial year 2024 Key takeaways
Slide 3: About TruScreen technology
For personal use only About TruScreen technology
Slide 4: World class technology made simple
4 WORLD CLASS technology made simple For personal use only Real-time, AI-enabled, primary cervical cancer screening device for detection of pre-cancerous and cancerous cervical tissue ► Optical and electrical measurements painlessly detect abnormalities in cervical tissue ► A Single Use Sensor (SUS)
Slide 5: 20 Years of Clinical Studies with 42,000 Patients
For personal use only 0 5000 10000 15000 20000 25000 30000 35000 40000 45000 Australia Australia China- Wang ling China- Zhang Wei Poland China- Lu Korea China- Zhang Wei China- Feng Korea China- Cui Ying Ying China- He Xiu Kui China-Li Xia China- Li Xi China- Weihong Li *Cumulative number of women
Slide 6: TruScreen transformation of cervical cancer screening
TruScreen transformation of cervical cancer screening For personal use only Moving from multi-step, expensive screening to Point-of-Care Solution Specimen Label, Packaging Microscopic Communication Collection and Transport Slide Preparation Fixation Staining Examination Interpretation Reporting of R
Slide 7: Trusted Clinical Performance
7 Trusted Clinical Performance For personal use only High sensitivity High specificity Extensive body in detecting in detecting of clinical CIN2+* CIN2+* evidence TruScreen® has been found TruScreen® has been to be as sensitive in found to be more specific Over 40,000 women in detecting CIN2+ as in
Slide 8: Cervical cancer elimination
For personal use only Cervical cancer elimination WHO priority in 2024
Slide 9: Cervical cancer is the fourth most common cancer in women globally
9 Cervical cancer is the fourth most common cancer in For personal use only women globally Globally, 604 000 new cases and 342 000 deaths were recorded in 2020 About 90% of these deaths occurred in low- and middle-income countries The highest rates are in Africa, Central America and South-East
Slide 10: Cervical Cancer Is A Global Public Health Issue
10 1 Cervical Cancer Is A Global Public Health Issue For personal use only Fourth most common cancer in ► 604,000 new cases and 342,000 deaths a year women worldwide, 1BN+ women ► Most diagnoses occur at working age (35-44) of screening age in LMICs ► 90% of new cases and deaths occur in LMICs The W
Slide 11: Screening most important for next decades
11 Screening most important for next 3 decades In 2020, the CCEMC published the For personal use only modelling of the CC elimination as well as commented on the status in Lower- and Middle-Income Countries (LMICs). Compared to the status quo, by 2030, vaccination alone would have minimal impact o
Slide 12: Screening needs to accelerate, APEC example
12 Screening needs to accelerate, APEC example For personal use only 1 APEC Economic Status Report: Cervical Elimination in the APAC region March 2023
Slide 13: Effective co-invest model with global distribution
13 Effective co-invest model with global distribution For personal use only Lean headquarters Recurring revenue stream from consumable SUS Intellectual Property Distributors Service & manufacturing Local knowledge End-users and influence End-user management Public and private hospitals and c
Slide 14: TruScreen's presence and markets
14 TruScreen’s presence and markets* For personal use only CE CE CE Russia European Union: Europe Europe CE Mark Europe 6.7 6.7 M 6.7 M M 13.4 M China China China ISO 13485 119.1 119.1 M 119 M M Registered with: Saudi 3.6 M TGA, Australia Mexico Vietnam MHRA, UK 10.7 M 8.3 M NMPA, China SFDA
Slide 15: Key achievements: Sales growth FY2024
For personal use only Key achievements Sales growth FY2024
Slide 16: China: TruScreen's largest market and growth opportunity
China: TruScreen’s largest market and growth opportunity For personal use only Remains TruScreen’s top market ● High government support for cervical cancer screening ● Made in China TruScreen status from 2021 – preferred market access in China FY 2024 Market Progress ● Record sales of SUS: YTD FY24
Slide 17: China cervical cancer screening market
17 China market, USD M, PBI Market Research 2020 For personal use only China Cervical Cancer Screening Market Historical and CAGR (USD Million), By Test Type, Forecast, USD Million* 2015 – 2026* 4000.0 16.0% 3500.0 14.0% 3000.0 12.0% 2500.0 10.0% 8.0% 2000.0 6.0% 1500.0 4.0% 1000.0 2.0% 500.0 0.0% 0
Slide 18: China and APAC market, recent growth exceeded expectations
18 China and APAC market, recent growth exceeded expectations For personal use only Business Market Insights June 2023: The Asia Pacific CIN & HR-HPV treatment market is expected to grow from US$ 2,738.94 million in 2023 to US$ 3,949.99 million by 2028. It is estimated to grow at a CAGR of 7.6%
Slide 19: China, TruScreen FY2024 installations
19 China, TruScreen FY2024 installations For personal use only 72 December 2023, pipeline 25 • 72 hospitals have obtained OBGYN department acceptance, 12 awaiting hospital approval • 25 hospitals have received TruScreen approval, awaiting tender By end of FY 2024 • 12 tenders won, awaiting hospital
Slide 20: China, potential for SUS pull through growth
20 China, potential for SUS pull through growth For personal use only The devices in China currently have an average pull through of 106 SUS per device per month, 24% growth in FY24 the potential average pull- through of SUS exceeds 290 per month Key accounts reach 500+ SUS A B C D E F pull throu
Slide 21: Vietnam
Vietnam Focus market with renewed focus on public hospital rollout For personal use only The Market Opportunity ● 24m women of screening Age*, booming economy and middle class ● No centralised screening programs FY2024 Market Progress ● Ministry Of Health (MOH) has listed TruScreen on the NationalTe
Slide 22: FY24 Other Markets
FY24 Other Markets For personal use only Zimbabwe ● Very successful Government screening program in Masvingo province, 14 000 women screened to date, ● Two tenders won in 2023 Saudi Arabia ● Commercial rollout commenced in FY24 ● Most private health insurers are reimbursing TruScreen procedure Mexic
Slide 23: Top achievements FY2024
23 Achievements: Top achievements FY2024 China: COGA Blue Book and CSCCP Guideline For personal use only entries Vietnam: MOH inclusion in the National Technical Sales and Revenue, Q1-Q3 FY2024: List SUS sales exceeded total of FY2023, 22% Saudi Arabia: commercial roll out and private health
Slide 24: Outlook strategy and goals FY2024-2025
For personal use only Outlook strategy and goals FY2024-2025
Slide 25: FY2024-FY2025 Strategy
25 FY2024- FY2025 Strategy Focus on 3 strategic drivers For personal use only Improve Strengthen Drive Growth operations partnerships • Double down on • Enhance marketing • Enhance relationships performance • Reduce cost of goods • Talk economics • Diversify deliberately (COGS) • Provide solutions S
Slide 26: Our Short Term Goals
26 Our Short Term Goals For personal use only Maximise Expand Grow Improve Seize the COGA Grow commercial Successfully expand Improve the gross Blue Book & presence in Africa, markets in margin by reducing CSCCP national Middle East, Central Zimbabwe, Saudi COGS guideline window to and Eastern Europ
Slide 27: Long Term Goals
27 For personal use only Expansion and adoption of technology in the screening cervical cancer guidelines in target markets Long Term Goals Development of technology toward diagnostics and treatment of cancers
Slide 28: Device installations and SUS sales FY2019-FY2025
28 Device installations and SUS sales FY2019- FY2025 For personal use only FY2019 - FY2023, actuals FY2024 - FY025, projections* 350 we are here 250000 300 200000 250 150000 200 150 100000 100 50000 50 0 0 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24* Mar '25* Installed Devices SUS Sales *This is
Slide 29: Key take-aways
Key take-aways Sales growth from SUS For personal use only consumable usage driven by increased device installed & use China remains the biggest market with huge opportunity Global growth commenced Transformative technology of the immediate future Cervical cancer elimination: international
Slide 30: www.truscreen.com
For personal use only www.truscreen.com ©
Slide 31: Contact us for more information
31 For personal use only Dr Beata Edling Guy Robertson CEO M - +61 419 569 993 Contact us Chief Financial Officer M – +61 407 983 270 E – beataedling@truscreen.com TruScreen for more E – guyrobertson@truscreen.com TruScreen information 36 Bradfield Road, CSIRO 36 Bradfield Road, CSIRO Lindfield West
Slide 32: Disclaimers
32 Disclaimers For personal use only This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information i
Slide 33: References
References For personal use only 1. WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news- room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer 2. WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020 3. Human papillomavirus and cancer (wh
TruScreen Group — Investor Presentation (February 2024) on 6ix